Bristol Myers Squibb
Search results
1 day ago · A U.S. judge has dismissed a lawsuit which claimed that BMS slow-walked its FDA approval of Breyanzi to avoid paying $6.4B to Celgene shareholders.
2 days ago · (Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi...
1 day ago · Bristol Myers Squibb won a legal victory as a New York judge dismissed a $6.4 billion lawsuit filed by UMB Bank on behalf of Celgene shareholders. The lawsuit alleged that Bristol Myers delayed drug approvals to avoid contingent value right (CVR) payments from its 2019 Celgene acquisition.
19 hours ago · Bristol-Myers Squibb Co. defeateda $6.4 billion lawsuit against it related to contingent value rights it issued when it purchased Celgene Corp., a federal court said.
3 days ago · Bristol-Myers Squibb reveals its new leadership after acquiring Celgene for $74 billion. The deal will create a cancer powerhouse, but also involves some changes and departures in the R&D and commercial divisions.
6 days ago · Former Celgene shareholders holding on for a windfall payment from Bristol-Myers Squibb tied to FDA approval of three late-stage drugs saw their hopes dashed as 2020 drew to a close.
Sep 5, 2024 · Celgene’s latest deal comes as it celebrates the sale of its blockbuster psoriasis therapy Otezla (apremilast) to Amgen for an impressive $13.4 billion, clearing the way for the $74 billion ...
